1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > CNS Drug News 05 OCTOBER 2015

CNS Drug News 05 OCTOBER 2015

  • October 2015
  • -
  • Espicom Business Intelligence
  • -
  • 24 pages

Industry Trend Analysis - Ocrelizumab Set To Fill Unmet Medical Need In PPMS
Industry Trend Analysis - Teva Stands To Win In Allergan/Impax Patent Battle
Industry Brief - CHMP Adopts Positive Opinion On Impax' Numient For PD
Industry Trend Analysis - Merck KGaA's Oral Cladribine Will Find Position In Crowded Market
Industry Brief - Biogen Licenses Worldwide Rights For Autoimmune Candidate From MTP
Industry Trend Analysis - Product Diversification Vital For ANI's Financial Security
Industry Brief - Betaconnect First Autoinjector For RRMS
Industry Brief - FDA Accepts Ontinua ER NDA Filing
Industry Brief - Copaxone Approved In Japan For Relapsing MS
Industry Brief - Medtronic Acquires Lazarus Effect
Industry Brief - Vanda Gets Favourable Ruling In Fanapt Suit
Industry Brief - FDA Accepts Vanda's Fanapt sNDA For Maintenance Treatment In Schizophrenia
Industry Brief - GW Reports Positive Top-Line Results From Cannabidiol Phase IIa Trial In Schizophrenia
Industry Trend Analysis - ITI-007's Advantage Over Competitors Will Secure Schizophrenia Market Share
Industry Trend Analysis - Europe Offers New Revenue Streams For Intuniv
Industry Brief - FDA Approves Vraylar For Bipolar I Disorder And Schizophrenia
Industry Trend Analysis - Patent Affirmation A Boon For Shire's Development
Industry Brief - Allergan, Mylan Launch Paliperidone Tablets
Industry Brief - Depomed Files Patent Infringement Suit Against Actavis Over Generic Nucynta ER
Industry Brief - First Patient Dosed In XaraColl MATRIX-2 Phase III Study
Industry Brief - Xenon Achieves Milestone In Pain Discovery Collaboration With Genentech
Industry Brief - Heron's HTX-011 Phase II Study In Postoperative Pain Meets Endpoints
Industry Trend Analysis - Zalviso's EMA Approval Is A Vital First Step For AcelRx
Industry Brief - Depomed Receives Favourable Decision Against Endo Pharmaceuticals Over Opana ER Patent
Industry Brief - CHMP Issues Positive Opinion On Ionsys In Postoperative Pain
Industry Trend Analysis - Astellas/Chromocell Agreement Increases Pipeline Diversity
Industry Brief - Jubilant Gains Zolmitriptan Approval
Industry Trend Analysis - Regeneron/MTP Collaboration In Asia Will Lead To Further Development
Industry Brief - FDA Approves Abuse-Deterrent MorphaBond ER
Industry Brief - FDA Accepts Probuphine NDA For Review
Industry Trend Analysis - Contrave Will Place Orexigen Back On Track
Industry Brief - Contrave NDA Submitted In South Korea
Industry Brief - FDA Accepts Sustol NDA For Review
Industry Brief - FDA Grant Alcobra's MDX Fast Track Designation For Fragile X Syndrome
Industry Brief - Alector Raises Funds To Advance Neurodegenerative Pipeline
Industry Brief - Strides To Acquire CNS Divisions Of Erstwhile Ranbaxy
Industry Brief - BioMotiv/Biogen Enter Neuroscience Collaboration
Industry Trend Analysis - Pharma Industry Will Need To Heed FTC's 'Product Hopping' Warning

Table Of Contents

CNS Drug News 05 OCTOBER 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorde ...

Schizophrenia - 5EU Drug Forecast and Market Analysis to 2025

Schizophrenia - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by Global Data

Schizophrenia - 5EU Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorder is characterized ...

Schizophrenia - US Drug Forecast and Market Analysis to 2025

Schizophrenia - US Drug Forecast and Market Analysis to 2025

  • $ 4995
  • Industry report
  • November 2016
  • by Global Data

Schizophrenia - US Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorder is characterized ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.